Insilico Medicine (03696) announced that its wholly-owned subsidiary, Insilico Medicine Technology (Shanghai) Co., Ltd., has recently signed a strategic cooperation agreement with Luoxin Pharmaceutical (002793.SZ).
Under the strategic cooperation agreement, the two parties intend to establish a long-term strategic partnership centered on innovative drug research and development, promoting the deep integration of artificial intelligence technology with disease-area expertise, research data, and R&D experience, and jointly exploring innovative drug development with clinical value and development potential.
The two parties will prioritize exploration in the fields of digestive system diseases, metabolic diseases, and other non-oncology chronic diseases, and will gradually expand to other disease areas mutually recognized by both parties based on actual progress.
The cooperation will be advanced according to the principles of "joint assessment, phased implementation, and project-by-project confirmation." Leveraging their respective resource advantages, technological foundations, and channel capabilities, the two parties aim to achieve complementary strengths and coordinated development, further enhancing the company's core competitiveness and supporting its long-term strategic layout.
Specific cooperation areas include: disease research and target discovery, innovative molecule discovery and optimization, empowerment of ongoing projects, R&D translation collaboration, technical and professional exchanges, and other cooperation matters agreed upon by both parties.
Comments